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ABSTRACT 
Conjunctivitis is defined as the inflammation of the conjunctiva. Allergic conjunctivitis is an acute, intermittent or chronic inflammation of the 
conjunctiva due to air borne allergens. Allergic reactions occur when the immune system is hypersensitive to normally harmless environmental 
substances, called allergens. Allergic conjunctivitis is an increasingly prevalent allergic reaction and currently 40% of global population is 
suffering from allergic conjunctivitis. Being an immunopathological disease, Conjunctival mast cell degranulation plays a major role in ocular 
allergic disease and so treatment options should be concentrated on preventing degranulation or of antagonizing the effects o f the primary 
mediator, histamine. Commonly used medications are: Topical OTC antihistamines (eg, ketotifen) , topical prescription antihistamines (eg, 
olopatadine, bepotastine, alcaftadine), NSAIDs (eg, ketorolac), or mast cell stabilizers (eg, nedocromil, cromolyn, azelastine) and can be used 
separately or in combination. In our study, the safety profile of Olopatadine 0.7% is comparable with fixed dose combination of Olopatadine 
0.1% and ketorolac tromethamine 0.4% by assessing the reduction in the severity of four parameters (ocular itching, conjunctival hyperemia, 
chemosis and tearing) of allergic conjunctivitis over 14 days of daily treatment. Ours is a Prospective case observational study conducted from 
August 2018-January 2019. A total of 80 patients were screened from the ophthalmology outpatient department. All the subjects who fulfilled 
eligibility criteria were randomly assigned in equal proportions into two arms i.e, group-1(patients receiving 0.7% olopatidine Hcl eye drops) & 
group-2( patients receiving 0.1% olopatidine Hcl+ 0.4% ketorolac tromethamine eye drops.). After the duration of treatment, the outcomes of 
the therapy were assessed and statistical analysis was done. It was observed that there was a significant difference in the percentage reduction 
of all the four parameters in the group 1 (i.e; patients treated with monotherapy) than the group 2 (i.e; patients treated with combination 
therapy). Also, the statistically obtained p value of the mean scores of final visits of four parameters were significantly lower in the first group 
than the second group from the second day through to the end of the study (p< 0.05). From this we concluded that monotherapy of 0.7% 
Olopatadine hydrochloride ophthalmic solution was found to be more effective in  reducing the clinical signs and symptoms of allergic 
conjunctivitis than dual combination therapy of 0.1% Olopatadine  hydrochloride + 0.4% Ketorolac tromethamine ophthalmic solution.  
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INTRODUCTION 
Conjunctivitis is defined as the inflammation of the 
conjunctiva. The conjunctiva is a thin membrane that lines 
the inner surface of the eyelids and sclera. Conjunctivitis can 
affect children and adults. Allergic conjunctivitis is acute, 
intermittent or chronic inflammation of the conjunctiva due 
to air borne allergens. Allergic reactions occur when the 
immune system is hypersensitive to normally harmless 
environmental substances, called allergens. Allergic 
conjunctivitis is caused by airborne allergens that come in 
contact with the eye e.g. pollen, cat/dog hair and moulds. 
Allergic conjunctivitis occurs very frequently and is seen 
most commonly in areas with high seasonal allergen and 
pollen counts. [1] 
Eye inflammation most commonly occurs in response to 
infection, allergy, surgery or trauma (i.e., blow to the eye, 
foreign body, chemical injury). It is important to control the 
duration and severity of inflammation and avoid scarring, as 
even a small amount of scarring of eye tissue can lead to 
irreversible vision impairment. An eye inflammatory 
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response is a generalized reaction to stimuli that typically 
fall into two classes: foreign substances such as bacteria or 
allergens or injuries to the eye tissue caused by trauma or 
surgery. Although inflammatory reactions commonly occur 
as part of the body's response to bacterial or viral infection, 
inflammation can also occur in the absence of infection. 
Allergens such as pollen, house dust or insect stings may 
provoke inflammation. Eye surgery is another, and perhaps 
the most common, cause of eye inflammation. Doctors 
naturally expect their patients to suffer eye inflammation as 
a direct result of eye surgery and, as such, treat their 
patients in advance for this outcome.[1, 2] 
Types: 
Allergic conjunctivitis may be divided into 5 major 
subcategories. 
1. Acute Allergic Conjunctivitis (AAC) 
2. Intermittent/Seasonal Allergic Conjunctivitis 
(IAC/SAC)  
3. Persistent/Perennial Allergic Conjunctivitis (PAC)  
4. Vernal Kerato conjunctivitis (VKC)  
5. Atopic Kerato conjunctivitis (AKC) 
6. Giant Papillary Conjunctivitis (GPC)  
Early diagnosis and treatment will help prevent the rare 
complications that can occur with this disease.[2, 3] 
Causes: 
Among the most common allergens that cause conjunctivitis 
are: 
 Pollen from trees, grass and ragweed 
 Animal skin and secretions such as saliva 
 Perfumes 
 Cosmetics 
 Skin medicines 
 Air pollution 
 Smoke 
 Dust mites 
 Balsam of Peru (used in food and drink for flavouring, 
in perfumes and toiletries for fragrance, and in 
medicine and pharmaceutical items for healing 
properties) 
Allergic conjunctivitis is due to a type I hypersensitivity 
reaction to a specific antigen. 
Seasonal allergic conjunctivitis (hay fever conjunctivitis) 
is caused by airborne mold spores, or pollen of trees, 
grasses, or weeds. It tends to peak during the spring, late 
summer, or early fall and disappear during the winter 
months—corresponding to the life cycle of the causative 
plant. 
Perennial allergic conjunctivitis (atopic conjunctivitis, 
atopic kerato conjunctivitis) is caused by dust mites, animal 
dander, and other non seasonal allergens. These allergens, 
particularly those in the home, tend to cause symptoms 
year-round. 
Vernal kerato conjunctivitis is a more severe type of 
conjunctivitis most likely allergic in origin. It is most 
common among males aged 5 to 20 who also have eczema, 
asthma, or seasonal allergies. Vernal kerato conjunctivitis 
typically reappears each spring and subsides in the fall and 
winter. Many children outgrow the condition by early 
adulthood. 
Some people may also experience allergic conjunctivitis in 
reaction to certain medications or substances dropped into 
the eyes, such as contact lens solution or medicated eye 
drops.[4,6] 
Pathophysiology: 
Allergic conjunctivitis is caused by an allergen-induced 
inflammatory response in which allergens interact with IgE 
bound to sensitized mast cells resulting in the clinical ocular 
allergic expression. The pathogenesis of allergic 
conjunctivitis is predominantly an IgE-mediated 
hypersensitivity reaction. Activation of mast cells induces 
enhanced tear levels of histamine, tryptase, prostaglandins 
and leukotrienes. This immediate or early response lasts 
clinically 20–30 min. 
Mast cell degranulation also induces activation of vascular 
endothelial cells, which in turn expresses chemokines and 
adhesion molecules such as intercellular adhesion molecule 
(ICAM), vascular cell adhesion molecule (VCAM). Other 
chemokines secreted include regulated upon activation 
normal T cell expressed and secreted (RANTES) chemokines, 
monocyte chemo attractant protein (MCP), interleukin (IL)-
8, eotaxin, macrophage inflammatory protein (MIP)-1 alpha. 
These factors initiate the recruitment phase of inflammatory 
cells in the conjunctival mucosa, which leads to the ocular 
late-phase   reaction [5- 8] 
Symptoms: 
The most common symptoms of allergic conjunctivitis 
include a red eye and discharge. Other signs and symptoms 
of conjunctivitis inflammation are itching, redness, swelling, 
pain, tearing, heat and redness, photosensitivity, foreign 
body sensation. Itching is the most frequent symptom and is 
considered the hallmark of ocular allergy.[1] 
Treatment: 
There are a number of treatments available for the 
symptoms of allergic conjunctivitis. In addition, basic eye 
care is important. 
Basic Eye Care: 
 Avoid rubbing the eyes. If itching is bothersome, use 
artificial tears, a cool compress, or antihistamine eye 
drops.  
 Minimize exposure to pollen by staying inside when 
possible, using air conditioning, and keeping car and 
home windows closed during the peak allergy seasons.  
 People with year-round allergic conjunctivitis should 
consider consulting an allergy specialist to determine 
which allergens are responsible for their symptoms 
(e.g. dust mites, cat dander, and others). 
Medications: 
People with sudden onset symptoms can use a combination 
antihistamine/ vasoconstrictor eye drop four times daily for 
up to two weeks. 
People with seasonal or year-round symptoms are usually 
treated with a combination  antihistamine/mast cell-
stabilizer eye drops. Most of these require a prescription.  
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An oral antihistamine may be most helpful when it is taken 
preventively (before symptoms develop). However, 
antihistamines may also be used to treat symptoms after 
they have started, although the greatest benefit may not be 
seen for several days. 
Non-sedating oral antihistamines include olopatadine 
hydrochloride, fexofenadine, Loratadine, Desloratadine, 
Cetirizine, and Levocetirizine. 
NSAIDS like ketorolac tromethamine can also be used in the 
treatment of allergic conjunctivitis. 
Diphenhydramine is a short-acting, sedating antihistamine 
that can be taken at bedtime to reduce night-time itching. 
Avoidance of known allergens, cold compresses, and use of 
tear supplements can reduce symptoms of allergic 
conjunctivitis; antigen desensitization is occasionally helpful.  
Topical OTC antihistamines (eg, ketotifen) are useful for 
mild cases. If these drugs are  insufficient, topical 
prescription antihistamines (eg, olopatadine, bepotastine, 
alcaftadine), NSAIDs (eg, ketorolac), or mast cell stabilizers 
(eg, nedocromil, cromolyn, azelastine) can be used 
separately or in combination. 
 Topical corticosteroids (eg, loteprednol, fluorometholone 
0.1%, prednisolone acetate 0.12% to 1% drops tid) can be 
useful in recalcitrant cases. 
 Because topical corticosteroids can exacerbate ocular 
herpes simplex virus infections (see Herpes Simplex 
Keratitis), possibly leading to corneal ulceration and 
perforation and, with long-term use, to glaucoma and 
possibly cataracts, their use should be initiated and 
monitored by an ophthalmologist. 
Topical cyclosporine may be helpful. Oral antihistamines (eg, 
fexofenadine, cetirizine, or hydroxyzine) can be helpful, 
especially when patients experience other allergic symptoms 
(eg, rhinorrhea).[1,4] 
Olopatadine Hydrochloride: 
Olopatadine hydrochloride ophthalmic solution has been 
available in concentrations of 0.1%, 0.2% and 0.7% for the 
treatment of allergic conjunctivitis and itching associated 
with allergic conjunctivitis.[9] 
Indication: 
Olopatadine hydrochloride ophthalmic solution treatment of 
ocular itching associated with allergic conjunctivitis.[9] 
Description: 
Olopatadine hydrochloride ophthalmic solution is a sterile 
ophthalmic solution containing olopatadine for topical 
administration to the eyes. Olopatadine hydrochloride is a 
white, crystalline, water-soluble powder with a molecular 
weight of 373.88 and a molecular formula of C21H23NO3 • 
HCl.[10] 
The Chemical Name: 11-[(Z)-3(dimethylamino) 
propylidene]-6-11dihydrodibenz [b,e] oxepin-2- acetic acid, 
hydrochloride.[11] 
 Each mL of solution contains an active ingredient [7.76 mg 
of olopatadine hydrochloride ( 7 mg olopatadine)] and the 
following inactive ingredients: povidone; hydroxypropyl-
gamma-cyclodextrin; polyethylene glycol 400; 
hydroxypropyl methylcellulose; boric acid; mannitol; 
benzalkonium chloride 0.015% (preservative); hydrochloric 
acid/sodium hydroxide (to adjust pH); and purified 
water.[11] 
Opthalamic solution has a pH of approximately 7.2 and an 
osmolality of approximately 300 m Osm /kg.[11] 
Mechanism of Action: 
Olopatadine is a mast cell stabilizer and a histamine H1 
antagonist. Decreases chemotaxis and also inhibits 
eosinophil activation.[10] 
Dosage Forms and Strengths: 
Ophthalmic solution:  
7.76 mg of olopatadine hydrochloride in one mL solution 
(0.7%) in a 4 mL bottle. [11] 
Dosage and Administration: 
The recommended dose is one drop in each affected eye 
once a day.[10] 
Adverse Reactions: 
 Symptoms similar to cold syndrome and pharyngitis were 
reported at an incidence of approximately 10%.  
Headaches have been reported at an incidence of 7%. 
The following adverse experiences have been reported in 
5% or less of patients: 
 Ocular: blurred vision, burning or stinging, conjunctivitis, 
dry eye, foreign body sensation, hyperemia, hypersensitivity, 
keratitis, lid edema, pain and ocular pruritus.  
Non-ocular: asthenia, back pain, flu syndrome, headache, 
increased cough, infection, nausea, rhinitis, sinusitis and 
taste perversion.[10,12] 
Ketorolac Tromethamine: 
Ketorolac tromethamine ophthalmic solution is a member of 
the pyrrolopyrrole group of nonsteroidal anti-inflammatory 
drugs (NSAIDs) for ophthalmic use. 
Ketorolac tromethamine  ophthalmic solution is supplied as 
a sterile isotonic aqueous  solution, with a pH of 
approximately 7.4.  
Ketorolac tromethamine  ophthalmic solution is a racemic 
mixture of R-(+) and S-(-)- ketorolac tromethamine. 
Ketorolac tromethamine may exist in three crystal forms. All 
forms are equally soluble in water. The pKa of ketorolac is 
3.5.  
This white to off-white crystalline substance discolors on 
prolonged exposure to light. The osmolality of ophthalmic 
solution is approximately 290 m Osml/kg.[15] 
Clinical Pharmacology: 
Mechanism of Action: 
 Ketorolac tromethamine is a nonsteroidal anti-
inflammatory drug which, when administered systemically, 
has demonstrated analgesic, anti-inflammatory, and anti-
pyretic activity. The mechanism of its action is thought to be 
due to its ability to inhibit prostaglandin biosynthesis.  
Indications And Usage: 
Ketorolac tromethamine ophthalmic solution is indicated for 
the reduction of ocular pain and burning/stinging. 
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Contraindications: 
Ketorolac tromethamine ophthalmic solution is 
contraindicated in patients with previously demonstrated 
hypersensitivity to any of the ingredients in the formulation. 
Adverse Reactions: 
The most frequently reported adverse reactions for 
ophthalmic solution occurring in approximately 1 to 5% of 
the overall population were conjunctival hyperemia, corneal 
infiltrates, headache, ocular edema and ocular pain.  
The most frequent adverse events reported with the use of 
ketorolac tromethamine ophthalmic solutions have been 
transient stinging and burning on instillation. These events 
were reported by 20% - 40% of patients participating in 
these other clinical trials. Other adverse events occurring 
approximately 1% - 10% of the time during treatment with 
ketorolac tromethamine ophthalmic solutions included 
allergic reactions, corneal edema, iritis, ocular inflammation, 
ocular irritation, ocular pain, superficial keratitis, and 
superficial ocular infections. [14] 
Dosage and Administration: 
 The recommended dose of ophthalmic solution is one drop 
two times a day in the effected eye. 
Pharmacokinetics Two drops of 0.4% ketorolac 
tromethamine ophthalmic solution instilled into the eyes of 
patients. [13] 
Aims& Objectives: 
The aim of the study is to evaluate the efficacy of 0.7 % 
w/vOlopatadine Hydrochloride Ophthalmic Solution and the 
fixed dose combination of 0.1% w/v Olopatadine 
Hydrochloride and0.4% w/v ketorolac tromethamine 
Ophthalmic Solution for the treatment of   Allergic 
Conjunctivitis. 
Primary Objective: 
To evaluate the efficacy of 0.7% w/v Olopatadine 
Hydrochloride Ophthalmic Solution compared with 0.1% 
w/v Olopatadine Hydrochloride and 0.4% w/v  ketorolac 
tromethamineOphthalmic Solution for the treatment of  
Allergic Conjunctivitis through four parameters of allergic 
conjunctivitis {ocular itching, conjunctival hyperemia , 
chemosis and tearing}. 
Secondary Objective: 
Change from baseline in ocular itching score on day 2 [at 24 
hrs (±1 hr) post first instillation of eye drops],day 7(±1day) 
and day 14(±1day) 
Change from baseline in conjunctival hyperemia score on 
days 2 [at 24 hrs (±1 hr) post first instillation of eye drops], 
7(±1day) and 14(±1day). 
Change from baseline in tearing score on days 2 [at 24 hrs(± 
hr) post first instillation of eye drops], 7(±1day) and 
14(±1day). 
Change from baseline in chemosis score on days 2 [at 24 
hrs(±1 hr) post first instillation of eye drops], 7(±1day) and 
14(±1day). 
To measure the outcomes following scales are used 
 Ocular Itching  Scale 
 Conjuctival Hyperemia Scale 
 Tearing Scale 
 Chemosis Scale 
MATERIALS AND METHODS 
Study Site: Outpatient department of Ophthalmology, 
Gandhi Hospital, Secunderabad. 
Study Period: August 2018-January 2019 
Study Duration:  6months 
Study Design:  Prospective case observational study 
 Study Disease: Allergic Conjunctivitis 
Study approval: Project is approved by Institutional Review 
Board. 
Sample size (N) : 80 subjects 
STUDY METHOD: 
 Preparation of structured documentation form for 
documentation of study cases (Annexure-I) and the 
informed consent form (Annexure-2) for patient 
consent. 
 Visit outpatient department on regular basis.  
 Review & collection of cases according to inclusion and 
exclusion criteria on regular basis. 
 Explain about the study to the patient and his/her 
attenders and seeking their consent to participate in 
the study. 
 Randomly providing the medications and explaining 
regarding the dose to be administrated. 
 Seeking their contact numbers for follow up process. 
 Collection of data. 
 Interpretation of data to generate result. 
 Analysis of result to obtain the final outcome by 
statistical application and submission 
Inclusion Criteria: 
 Male or female subjects, aged 10 years to70 years 
(both inclusive). 
 Subjects with diagnosis of ocular itching associated 
with allergic conjunctivitis in one or both the eyes. 
 Subjects willing to discontinue contact lens wear for at 
least 72 hours prior to instillation of eye drops. 
Exclusion Criteria: 
 Subjects with any contraindications or 
hypersensitivities to the use of the study medication or 
their components. 
 Subjects who are blind or subjects with single eye will 
be excluded from the study.  
 Patients with Visual acuity of 20/80 in any eye. 
 Subjects with known case of persistent dry eye 
syndrome or currently on treatment for dry eyes. 
 Subjects with Vernal Kerato-conjunctivitis (VKC), 
Atopic Kerato-conjunctivitis (AKC) and Giant Papillary   
Conjunctivitis (GPC) will be excluded from the study.   
Over all Study Design: 
A simple randomised comparative study to evaluate the 
efficacy of 0.7% w/v Olopatadine Hydrochloride Ophthalmic 
Solution compared with fixed dose combination of 0.1% w/v 
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Olopatadine Hydrochloride and 0.4%w/v ketorolac 
tromethamine Ophthalmic Solution for the treatment of 
Allergic Conjunctivitis. During the screening, subjects who 
gave consent are evaluated for all the eligibility criteria. 
Eligible subjects clinically diagnosed with ocular itching 
associated with allergic conjunctivitis and who are between 
10 to 70 years of age are considered for the study. Subjects 
fulfilling all the inclusion criteria and none of the exclusion 
criteria are randomized on day 1. 
Subjects are assigned one of the two groups i.e. Group 1 or 
Group 2 consisting of 0.7% olopatadine hydrochloride or 
fixed dose combination of 0.1% olopatadine and 0.4% 
ketorolac tromethamine respectively. Subjects who are 
categorised under group 1 are instructed to instil one drop 
in each affected eye once a day and subjects who are 
categorised under group 2 are instructed to instil one drop 
in each effected eye twice  a day . Subjects are instructed to 
instil first drop at site in front of the principal investigator 
on the day of randomization.  
Subject is assessed for ocular itching, conjunctival 
hyperemia, tearing and chemosis during the entire study 
period. Physical examination and vitals are taken at all the 
visits till the end of study. Adverse events and concomitant 
medications are also assessed from Baseline to visit 3/end of 
study visit. Visual acuity test and slit lamp biomicroscopy 
was conducted on baseline visit. 
All subjects are assessed for primary endpoint i.e. Change 
from baseline in ocular itching score on days 2 (at 24 hrs (±1 
hr) post first instillation of eye drops), 7 and 14, secondary 
endpoint i.e. Change from baseline in conjunctival 
hyperemia grade on day 2 (at 24 hrs (±1 hr) post first 
instillation of eye drops), 7 and 14, Change from baseline in 
tearing score at the end of days 2 (at 24 hrs (±1 hr) post first 
instillation of eye drops ), 7 and 14, Change from baseline in 
chemosis score at the end of day 2 (at 24 hrs (±1 hr) post 
first instillation of eye drops), 7 and 14 and At the final visit 
overall response of clinical cure & overall assessment is 
done by Patients and Physician. Subjects are assessed for the 
efficacy of both the study medications. 
Statistical Analysis: 
Descriptive statistical analysis has been carried out in the 
present study whenever necessary. 
RESULTS 
A total of 80 patients with allergic conjuctivities were 
assigned one of the two groups i.e. Group 1 or Group 2 
consisting of 0.7% olopatadine hydrochloride or fixed dose 
combination of 0.1% olopatadine and 0.4% ketorolac 
tromethamine during the corresponding time period of 
August 2018-January 2019. 
Table-1: Distribution of Patients on the basis of Age. 
S.no Age No. of  Patients 
1 11-20 2 
2 21-30 22 
3 31-40 21 
4 41-50 24 
5 51-60 10 
6 61-70 1 
 
 
 
Fig-1: Distribution of patients on the basis of Gender. 
Total sample Size:  N=80,  
40 patients were treated with monotherapy (Olopatadine 
Hcl 0.7%w/v) and 40 patients were treated with dual 
combination therapy (Olopatadine Hcl 0.1% w/v+ Ketorolac 
tromethamine 0.4%w/v). 
Group-1 consists of 40 patients who are treated with 0.7% 
w/v olapatadine hydrochloride ophthalmic solution. The 
mean ocular itching scores of these patients on baseline, 
second visit and final visit are - 3.5125, 1.9375 and 0.3250 
respectively.  
The mean conjunctival hyperemia scores of Group-1 patients 
on baseline, second visit and final visit are - 3.15, 1.6375 and 
0.3250 respectively. 
The mean chemosis scores of Group-1 patients on baseline, 
second visit and final vist are- 2.9250, 1.0750 and 0.20  
respectively . 
The mean tearing scores of Group-1 patients on baseline, 
second visit and final visit are- 2.9250, 1.0750 and 0.20  
respectively. 
Group-2 consists of 40 patients who are treated with 
olapatadine hydrochloride 0.1% w/v + ketorolac 
tromethamine 0.4 %  w/v ophthalmic solution. 
The mean ocular itching scores of Group-2 patients on 
baseline, second visit and final visit are- 3.6875, 2.43 and 
0.9250 respectively.  
The mean conjunctival hyperemia scores of Group-2 patients 
on baseline, second visit and final visit are- 3.57, 2.3750 and 
0.850 respectively. 
The mean chemosis scores of Group-2 patients on baseline, 
second visit and final visit are- 2.9625, 1.7250 and 0.650 
respectively. 
The mean tearing scores of Group-2 patients on baseline, 
second visit and final visit are- 2.8520, 1.5750 and 0.65 
respectively. 
Table 2: Percentage Reduction in Severity of Allergic 
Conjunctivitis Parameters at the end of the study from 
Baseline: 
Parameters  Monotherapy  Combinational  
Therapy  
Ocular itching  90.74% 74% 
Conjunctival 
hyperemia 
89.7% 76% 
Chemosis score 93% 78.05% 
Tearing score 100% 76.9% 
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DISCUSSION 
By comparing the treatment outcomes of both Group-1 and 
Group-2 for the study period, i.e. from baseline to final visit 
of treatment, the following observations are made: 
 It was observed that 52.5% of patients had a complete 
cure of ocular itching when treated with 0.7% 
olopatadine hydrochloride eye drops while 12.5% of 
patients had a complete cure of ocular itching when 
treated with FDC of 0.1% olopatadine hydrochloride 
and 0.4% ketorolac tromethamine eye drops. 
 About 67.5% of patients had a complete cure of 
conjunctival hyperemia when treated with 0.7% 
olopatadine hydrochloride eye drops while 12.5% of 
patients had a complete cure of conjunctival hyperemia 
when treated with FDC of 0.1% olopatadine 
hydrochloride and 0.4% ketorolac tromethamine eye 
drops. 
 In case of chemosis score 80% of patients had a 
complete cure when treated with 0.7% olopatadine 
hydrochloride eye drops while 42.5% of patients had a 
complete cure of  chemosis when treated with FDC of 
0.1% olopatadine hydrochloride and 0.4% ketorolac 
tromethamine eye drops. 
 It was observed that 100% of patients had a complete 
cure of tearing when treated with 0.7% olopatadine 
hydrochloride eye drops while 35% of patients had a 
complete cure of tearing when treated with FDC of 
0.1% olopatadine hydrochloride and 0.4% ketorolac 
tromethamine eye drops 
 In our study the ADR that we observed was headache 
in about 2.4% of our total population(80 patients). The 
concomitant medication prescribed by the physician 
was Paracetemol 325mg BD. 
When the clinical parameters of eyes treated with 0.7% 
OlopatadineHcl were compared with those treated 
with FDC of 0.1% Olopatadine Hcl and 0.4% Ketorolac 
promethazine: 
 The mean scores of ocular itching was found to be 
lower in 0.7% Olopatadine Hcl (0.3250) compared to 
0.1% Olopatadine Hcl and 0.4% Ketorolac 
tromethamine (0.9250). 
 The mean scores of conjunctival hyperemia was found 
to be lower in 0.7% Olopatadine Hcl (0.3250) 
compared to 0.1% Olopatadine Hcl and 0.4% Ketorolac 
tromethamine (0.850). 
 The mean scores of chemosiswas found to be lower in 
0.7% Olopatadine Hcl (0.20) compared to 0.1% 
Olopatadine Hcl and 0.4% Ketorolac tromethamine 
(0.650). 
 The mean scores of tearing was found to be lower in 
0.7% Olopatadine Hcl (0) compared to 0.1% 
Olopatadine Hcl and 0.4% Ketorolac tromethamine 
(0.65). 
Also when the percentage reduction in the severity of 
all the four parameters were compared in both groups 
i.e, patients treated with mono and combination 
therapy, the following outcomes were observed: 
 In case of monotherapy, the percentage reduction in 
the severity of ocular itching score was 90.74% 
whereas the percentage reduction in the severity of 
ocular itching in case of combinational therapy 
was74%. 
 The percentage reduction in the severity of 
conjunctival hyperemia score in 
monotherapywas89.7% whereas the percentage 
reduction in the severity of  conjunctival hyperemia in 
case of combinational therapy was76.1%. 
 In case of monotherapy, the percentage reduction in 
the severity of chemosis score was93.1% whereas the 
percentage reduction in the the severity of chemosis in 
case of combinational therapy was78.05%. 
 The percentage reduction in the severity of tearing 
score in monotherapywas100% whereas the 
percentage reduction in the the severity of tearing 
score in case of combinational therapy was76.9%. 
These observations indicate that there was a significant 
difference in the percentage reduction of all the four 
parameters in the group 1 (i.e; patients treated with 
monotherapy) than the group 2 (i.e; patients treated with 
combination therapy). 
The statistically obtained p value of the mean scores of final 
visits of both groups was 0.001 .Thus the scores of four 
parameters (ocular itching, conjunctival hyperemia, 
chemosis and tearing) were significantly lower in the first 
group i.e patients who received monotherapy than the 
second group i.e patients who received combinational 
therapy from the second day through to the end of the study        
(p< 0.05). 
CONCLUSION 
Both the monotherapy of 0.7% Olopatadine hydrochloride 
and dual combination therapy of 0.1% Olopatadine 
hydrochloride + 0.4% Ketorolac tromethamine ophthalmic 
solution were found to be effective in alleviating the clinical 
signs and symptoms of allergic conjunctivitis. However by 
comparing the parameters of allergic conjunctivitis in both 
the study Groups  such as ocular itching, conjunctival 
hyperemia, chemosis and tearing, monotherapy of 0.7% 
Olopatadine hydrochloride ophthalmic solution was found 
to be more effective in reducing the clinical signs and 
symptoms of allergic conjunctivitis than  combination 
therapy of 0.1% Olopatadine hydrochloride + 0.4% 
Ketorolac tromethamine ophthalmic solution. 
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ABBREVATIONS USED 
AA-ACUTE ALLERGIC CONJUNCTIVITIS 
AKC-ATOPIC KERATO CONJUNCTIVITIS 
eg.-EXAMPLE 
FDC-FIXED DOSE COMBINATION 
GPC-GIANT PAPILLARY CONJUNCTIVITIS 
H1-HISTAMINE 1 RECEPTOR 
HCl-HYDROCHLORIC ACID 
IAC/SAC-INTERMITTENT/SEASONAL ALLERGIC 
CONJUNCTIVITIS 
ICAM-INTERCELLULAR ADHESION MOLECULE 
IgE-IMMUNOGLOBULIN E 
IL-  INTERLEUKIN 
MCP-MONOCYTE CHEMO ATTRACTANT PROTEIN 
Mg-MILLI GRAM 
MIP-MACROPHAGE INFLAMMATORY PROTEIN 
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ml.-MILLI  LITERS 
NSAIDS-NON STEROIDAL ANTI INFLAMMATORY DRUGS 
Osm/kg-OSMATIC CONCENTARION/KILO GRAM 
PAC-PERSISTENT/PERENNIAL ALLERGIC CONJUNCTIVITIS 
pH-POTENTIAL/POWER/CONCENTARTION OF HYDROGEN  
pKa-ACID DISSOCIATION CONSTANT 
RANTES-REGULATED UPON ACTIVATION NORMAL T CELL 
EXPRESSEDAND SECRETED 
SAC-SEASONAL ALLERGIC CONJUNCTIVITIS 
V-VOLUME 
VCAM-VASCULAR CELL ADHESION MOLECULE 
VKC-VERNAL KERATO CONJUNCTIVITIS 
w/v-WEIGHT / VOLUME 
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